Alexion Pharmaceuticals will buy a new facility in Rhode Island to make its experimental drug, Soliris, for a rare blood disorder, according to a Reuters report. Soliris is intended to treat Paroxysmal Nocturnal Hemoglobinuria, which affects between 8,000 and 10,000 people in the U.S. and Europe and causes red blood cells to be attacked and destroyed by the body’s own immune system. The drug will be filed in the second half of 2006 with the FDA and EMEA. The drug Soliris is presently manuf...